Board Changes - IM Cannabis Corp. announced the resignation of Messrs. Shmulik Arbel and Brian Schinderle from the Board, Audit Committee, and Compensation Committee effective September 15, 2025 [1][2] - Messrs. Asaf Yitzhaik and Eli Zamir have been appointed to the Board and the Audit Committee to fill the vacancies created by the resignations, with Mr. Zamir also joining the Compensation Committee [2] New Board Members - Mr. Yitzhaik has over three decades of experience in retail and real estate, owning ASI Glasses and holding directorships in several publicly traded companies [3] - Mr. Zamir has extensive expertise in finance and capital markets, having served as CEO of an underwriting firm and CFO of a public real estate company, and currently leads M&A and financing activities in the renewable energy sector [4] Leadership Changes - Mr. Oz Adler has been appointed as the new Chairman of the Board, replacing Mr. Oren Shuster, who remains the Chief Executive Officer and a director [5] Strategic Review - The Company is conducting an ongoing strategic review and is exploring the introduction of additional business activities to enhance long-term growth opportunities and create further shareholder value [6] Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on sustainable and profitable growth in these high-value markets [7] - The Company operates a transnational ecosystem that includes importing and distributing cannabis, retail pharmacies, online platforms, and logistical hubs in Israel, as well as distributing cannabis to pharmacies in Germany through Adjupharm GmbH [8]

Core Points - IM Cannabis Corp. has regained compliance with Nasdaq Listing Rule 5550(b)(1), maintaining stockholders' equity of at least $2,500,000, allowing its common stock to continue trading on the Nasdaq Capital Market [1] Company Overview - IM Cannabis Corp. is an international cannabis company providing premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets [2] - The company operates a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain, focusing on responsible growth and regulatory compliance [2] Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis to medical patients, utilizing proprietary data and patient insights [3] - The company runs medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel to ensure safe delivery and quality control of its products [3] - In Germany, IM Cannabis operates through Adjupharm GmbH, distributing cannabis to pharmacies for medical cannabis patients [3]

TORONTO and GLIL YAM, Israel, Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024 Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to ...

Core Insights - IM Cannabis Corp. reported strong profit and margin growth in Q2 2025 despite a revenue decline due to external challenges such as the ongoing war in Israel and supply chain delays [1][2][12] Financial Highlights - Revenue for Q2 2025 was CAD 12.7 million, a 14% decrease from CAD 14.8 million in Q2 2024, primarily due to a CAD 5.3 million decline in Israel, partially offset by CAD 3.3 million growth in Germany [12] - Gross profit increased by 306% to CAD 3.4 million compared to CAD 0.8 million in Q2 2024, with gross margin rising to 27% from 6% [11][12] - Non-IFRS Adjusted EBITDA showed a profit of CAD 0.1 million in Q2 2025, a 105% improvement from a loss of CAD 2.3 million in Q2 2024 [2][12] - Operating expenses remained stable with a slight increase of 2% to CAD 3.8 million compared to CAD 3.7 million in Q2 2024 [12] Management Commentary - The CEO highlighted the challenges posed by the war and supply chain issues but expressed optimism about the company's profitability and margin growth, indicating a strong long-term strategy [2] - The CFO emphasized disciplined cost management and operational efficiency as key factors in achieving margin expansion despite the revenue decline [2] Company Overview - IM Cannabis Corp. operates in the medical cannabis markets of Israel and Germany, leveraging a data-driven approach and a globally sourced product supply chain [8][9] - The company aims to amplify its commercial and brand power while adhering to strict regulatory environments [8]

TORONTO and GLIL YAM, Israel, Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens. About IM Cannabis Corp. The IMC ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveragin ...

TORONTO and GLIL YAM, Israel, July 31, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, effective July 30, 2025 (the "Closing Date") it has closed a private placement offering (the "Offering"), through the issuance of 2,050,000 units (each a "Unit") at a price per Unit of C$2.7427 for gross proceeds of C$5,622,522, approximately US$4,100,000, based on an exchange rate ...

Core Viewpoint - IM Cannabis Corp. has filed a shelf registration statement with the SEC, allowing the company to offer and sell up to $50 million of its securities, including common shares, warrants, and units, depending on market conditions and capital needs [1][2]. Company Overview - IM Cannabis Corp. is a leading medical cannabis company operating in Israel and Germany, focusing on providing premium cannabis products to medical patients in these significant markets [5]. - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain [5]. Operations - In Israel, IM Cannabis operates through subsidiaries that import and distribute cannabis, manage medical cannabis retail pharmacies, and utilize online platforms for distribution [6]. - In Germany, the company distributes cannabis to pharmacies through its subsidiary, Adjupharm GmbH, catering to medical cannabis patients [6]. Shelf Registration Details - The shelf registration allows the company to sell securities on a registered basis, with specific terms and prices to be determined at the time of offering [2][3]. - The registration does not obligate the company to sell any specific amount of securities, as future offerings will depend on market conditions and the company's discretion [3].

Group 1 - IM Cannabis Corp. will be delisted from the CSE at market close on June 2, 2025 [1][2][3] - The company will continue to trade on Nasdaq after the delisting [1][2]

Financial Data and Key Metrics Changes - In Q1 2025, the company achieved a net profit with an 87% improvement in gross margin compared to Q1 2024 [6] - Adjusted EBITDA in Q1 2025 resulted in a profit of $600,000, an improvement of almost $3,000,000 from an adjusted EBITDA loss of $2,200,000 in Q1 2024 [10] - Revenues for Q1 2025 were $12,500,000, a 4% increase from $12,100,000 in Q1 2024 [10] - Gross profit for Q1 2025 was $3,400,000, a 94% increase from $1,800,000 in Q1 2024 [12] - Net profit for Q1 2025 was approximately $200,000, compared to a loss of $6,000,000 in Q1 2024, marking a $6,200,000 improvement [13] Business Line Data and Key Metrics Changes - The German business grew 569% compared to Q1 2024, significantly offsetting a 66% decline in Israeli revenue [7][10] - Germany's share of total revenue in Q1 2025 increased to 62%, reflecting favorable market conditions and growing demand [11] Market Data and Key Metrics Changes - The company launched 12 new strains in Germany, contributing approximately €3,000,000 or 39% of cannabis flower sales in the region [6] - The decline in Israeli revenue was attributed to the cancellation of the Orenin deal, resulting in a revenue decrease of approximately $3,500,000 compared to Q1 2024 [11] Company Strategy and Development Direction - The company is focusing on execution and resource allocation to areas with the highest return on investment (ROI) [6] - Cost-cutting measures from shifting production facilities in Israel are positively impacting financial results, leading to increased gross margins [8] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the internal progress made strategically and operationally, which is now reflected in financial results [15] - The company aims to continue executing its strategy to maintain profitability [15] Other Important Information - Total assets as of March 31, 2025, were $44,934,000, an increase of 15% from $39,188,000 as of December 31, 2024 [13] - Total liabilities increased to $41,761,000, a 16% rise from $36,042,000 as of December 31, 2024 [14] Q&A Session Summary Question: Importance of the upcoming meeting regarding the 25% ownership of Focus - Management indicated that the approval is crucial for regulatory compliance and to facilitate the transition of long-term loans to equity, which is necessary for tax purposes [19][20]

Financial Data and Key Metrics Changes - In Q1 2025, the company achieved a net profit with an 87% improvement in gross margin compared to Q1 2024 [5] - Adjusted EBITDA in Q1 2025 resulted in a profit of $600,000, an improvement of almost $3,000,000 from an adjusted EBITDA loss of $2,200,000 in Q1 2024 [8] - Revenues for Q1 2025 were $12,500,000, a 4% increase from $12,100,000 in Q1 2024, primarily driven by growth in Germany [8][10] - Gross profit for Q1 2025 was $3,400,000, a 94% increase from $1,800,000 in Q1 2024 [10] - Net profit for Q1 2025 was approximately $200,000, compared to a loss of $6,000,000 in Q1 2024, marking a $6,200,000 improvement [11] Business Line Data and Key Metrics Changes - The German business grew by 569% compared to Q1 2024, significantly offsetting a 66% revenue decline in Israel [6][8] - The company launched 12 new strains in Germany, contributing approximately €3,000,000 or 39% of cannabis flower sales in that market [5] - The decline in Israeli revenue was attributed to the cancellation of the Orenin deal, resulting in a decrease of approximately $3,500,000 compared to Q1 2024 [9] Market Data and Key Metrics Changes - Germany's share of total revenue in Q1 2025 increased to 62%, reflecting favorable market conditions and growing demand [9] - The cost of revenue decreased by 12% to $9,100,000 in Q1 2025, down from $10,300,000 in Q1 2024 [9] Company Strategy and Development Direction - The company is focusing on execution and resource allocation to areas with the highest return on investment (ROI) [5] - The strategic shift towards the German market is evident, with significant growth in that region while managing operational efficiencies [6][8] Management's Comments on Operating Environment and Future Outlook - Management expressed pride in the team's efforts and noted that the efficiencies and integration from the past two years are starting to reflect in financial results [6][11] - The company aims to continue executing its strategy and maintain profitability moving forward [7] Other Important Information - Total assets as of March 31, 2025, were $44,934,000, an increase of 15% from $39,188,000 as of December 31, 2024 [11] - Total liabilities increased by 16% to $41,761,000 as of March 31, 2025, compared to $36,042,000 as of December 31, 2024 [12] Q&A Session Summary Question: Importance of the upcoming meeting for accepting 25% ownership of Focus - Management indicated that this is a long process on the regulatory side and is crucial for clearing balances between companies and moving long-term loans to equity [17][18] - The need to hold 100% of the Focus shares is based on tax regulations to avoid issues with tax authorities [19]